Autopsy report · NCT00746421

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

“Sponsor withdrew funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 32 participants enrolled.
• Results were posted on the registry 1 year 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Emory University

Sponsor type

University, hospital or other

Conditions

Bipolar Disorder; Cognitive Impairment

Interventions

Quetiapine XR; Placebo

Participants

32

Sites

2

Countries

United States

Trials that died the same way

• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (96% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (91% match in meaning)
• Study of Regional Cerebral Oxygenation and Brain Blood Volume Changes During Carotid Endarterectomy Using the NeurOS System
  “sponsor withdrew” (90% match in meaning)
• Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
  “Sponsor withdrew support” (89% match in meaning)
• ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children
  “Withdrawal of funding from primary sponsor” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.